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Abstract: Snakebite envenoming represents a neglected tropical disease that has a heavy 
public health impact worldwide, mostly affecting poor people involved in agricultural 
activities in Africa, Asia, Latin America and Oceania. A key issue that complicates the 
treatment of snakebite envenomings is the poor availability of the only validated treatment 
for this disease, antivenoms. Antivenoms can be an efficacious treatment for snakebite 
envenoming, provided they are safe, effective, affordable, accessible and administered 
appropriately. The shortage of antivenoms in various regions, particularly in Sub-Saharan 
Africa and some parts of Asia, can be significantly alleviated by optimizing the use of 
current antivenoms and by the generation of novel polyspecific antivenoms having a wide 
spectrum of efficacy. Complementing preclinical testing of antivenom efficacy using in vivo 
and in vitro functional neutralization assays, developments in venomics and antivenomics 
are likely to revolutionize the design and preclinical assessment of antivenoms by being 
able to test new antivenom preparations and to predict their paraspecific neutralization to 
the level of species-specific toxins. 
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1. Introduction: Snakebite Envenoming and the Challenge of Generating Effective Antivenoms 
Snakebite envenoming is largely a neglected threat to public health that affects some of the world’s 
poorest rural communities, mainly those involved in subsistence farming and livestock grazing activities 
in tropical and subtropical regions of Africa, Asia, Latin America and Oceania. An estimated 5.5 million 
people are bitten by snakes each year, resulting in about 400,000 amputations and over 100,000 deaths; 
however, the true scale of this “disease of poverty” may be much greater than these hospital-based 
statistics, since many affected people do not attend health facilities [1–4]. Persistent underestimation of 
their true morbidity and mortality has made snakebites the most neglected of all of the World Health 
Organization (WHO)’s “neglected tropical diseases”, downgrading its public health importance. 
Moreover, the WHO recently moved snakebite envenoming to the category of “neglected tropical 
condition”, further reducing its relevance and thereby affecting the global awareness of the magnitude of 
this pathology. Strategies to address this neglect should include the improvement of affordable, effective 
antivenoms [3,5–8], the timely administration of which remains the only specific treatment for 
envenoming [9], more than a century after the development of the first serum antivenimeux by  
Calmette [10–12] and Phisalix and Bertrand [13,14] simultaneously, but independently, in 1894.  
In addition, the struggle against snakebite envenoming should include other aspects, such as improved 
statistics on morbidity and mortality, adequate access and distribution of safe and effective antivenoms 
in the public health system, training of health staff in the effective management of this disease and 
promotion of preventive campaigns at the local community level, among other goals. This series of tasks 
demand, in turn, the involvement of a large spectrum of stakeholders in diverse fields. 
More than 45 commercial or government antivenom producers exist around the world [15]. However, 
the lack of financial incentives in a technology that has remained relatively unchanged for the better part of 
the second half of the 20th Century, along with dwindling markets and a lack of leadership from global 
public health organizations, have made antivenom production a field of limited improvements and very 
little innovation [7]. Snake antivenoms became scarce or non-existent as poor commercial incentives forced 
some manufacturers to leave the market and others to downscale production or increase the price, leading to 
a decline in the availability and accessibility for these life-saving antidotes to the millions of rural poor most 
at risk from snakebites in low and middle-income countries [3]. Furthermore, many manufacturing 
laboratories in public institutions have suffered a lack of investment and renewal of their technological 
platforms, together with deficient training of their staff, thereby affecting the quality and quantity of their 
antivenoms. To raise the awareness of public health authorities on the relevance of the snakebite problem 
and to ensure supplies of effective antivenoms in deficitary parts of the world, several initiatives have 
emerged in the last decade. In 2008, members of the international toxinology community established the 
Global Snakebite Initiative [16,17]. Some of the goals of this organization include advocacy on the 
seriousness of this health problem, together with the promotion of research initiatives to improve 
epidemiological and clinical knowledge of envenomings and initiatives to improve training of health 
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staff and antivenom quality control and accessibility in some regions of the world [2,5,18,19]. The GSI 
strategy has also the goal of coupling modern proteomics, immunological, pharmacological and 
molecular biological techniques to the quest for improved therapeutics and the understanding of the 
underlying pathophysiology and clinical manifestations of snakebite envenomings [4,20–23]. 
A key technical issue concerning the generation of new antidotes for snakebite envenoming is the 
design of improved immunization mixtures in such a way that the resulting antivenoms are effective 
against most venoms of the medically-relevant snake species within the geographical range where these 
antivenoms are intended to be used. This purpose is not trivial given the well-documented occurrence of 
venom variability at the genus, species, subspecies, population and individual levels [24]. The variability of 
venom composition may endow snakes with the capability to adapt to different ecological niches. This is 
clearly evident for highly adaptable snake species of a wide geographical distribution in which allopatric 
venom variation may result in variable clinical presentations of envenomings [23,25]. In addition, 
variation in venom composition is dictated by different genomic and postgenomic mechanisms [26,27], 
and phenotypic venom variation across conspecific populations often involves ontogenetic shifts in 
venom protein expression [23]. Furthermore, venom is evolutionarily a highly labile trait, even among 
very closely-related taxa [28,29], preventing the prediction of venom composition and toxic activity 
based on phylogenetic distance. For instance, species within the genus Crotalus express either Type I 
(high levels of metalloprotease and low toxicity) or Type II (low metalloprotease, high toxicity) venoms, 
which result in completely different envenomings from a pathophysiological standpoint, and these 
venom phenotypes exhibit no phylogenetic relationship [30]. Furthermore, the finding of different 
evolutionary solutions within arboreal Bothriechis taxa for the same trophic purpose [31] (Figure 1) 
strengthens the view that phylogeny cannot be invoked as the sole criterion for species selection for 
antivenom production. 
The occurrence of ontogenetic, geographic and individual intraspecific venom variability highlights 
the necessity of using pooled venoms as a representative sample for antivenom manufacture, and a 
thorough study of clinical, epidemiological, immunological, proteomic and toxicological information 
may contribute to the design of the venom mixtures for immunization. These methodological approaches 
include classical biochemical and state-of-the-art proteomic analysis of venoms, the study of the 
toxicological profile of venom effects using in vivo and in vitro tests, and the investigation of the 
immunological cross-reactivity of antivenoms against homologous and heterologous venoms. 
Knowledge on the paraspecificity of antivenoms is not only of applied importance to optimize the 
production strategy of a novel antivenom, but also for predicting the full clinical range of existing 
antivenoms against homologous and heterologous venoms. To this end, a platform has been developed 
to explore the neutralizing ability and immunological cross-reactivity of antivenoms through a 
combination of methodologies that will be briefly discussed. 
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Figure 1. Highly divergent toxin compositions in phylogenetically-close snake taxa. Venom 
components of four Bothriechis species that inhabit Costa Rica were assigned to protein 
families, and their abundances were estimated, by using the “snake venomics” analytical 
strategy. As shown in the corresponding pie charts summarizing protein family abundances (%), 
the venom of Bothriechis lateralis is dominated by metalloproteinases, whereas small 
peptides of the vasoactive type are predominant in the venom of B. supraciliaris. On the 
other hand, B. schlegelii venom contains the highest proportion of phospholipases A2, while 
B. nigroviridis venom completely lacks metalloproteinases and presents a high percentage of 
an unusual phospholipase A2 recently characterized as a crotoxin-like complex, found for the 
first time in a non-rattlesnake New World pit viper. In addition, a novel protein type for 
snake venoms (Kazal-type proteinase inhibitor-like) was found in B. schlegelii and  
B. supraciliaris, but not in the other two species of this genus. Protein family abbreviations 
correspond to: SVMP, metalloproteinase; PLA2, phospholipase A2; SP, serine proteinase; 
CRISP, cysteine-rich secretory proteins; CTL, C-type lectins/lectin-like; VEGF, vascular 
endothelial growth factor; LAO, L-amino acid oxidase; NUCL, nucleotidase; DIS, disintegrin; 
PEP, small peptide; KAZ, Kazal-type proteinase inhibitor-like. Data adapted from  
Lomonte et al. [32]. 
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Figure 1. Cont. 
 
2. Biochemical and Toxinological Toolbox for the Preclinical Assessment of Antivenom Efficacy 
The analysis of the ability of an antivenom to neutralize the most relevant toxic activities of the snake 
venoms for which it was designed is a preclinical requisite before it can go into clinical trials and is 
approved for medical use. Simple experimental protocols have been developed to assess the ability of 
antivenoms to neutralize the most relevant toxic effects of snake venoms [22,33–37]. The most 
widely-used protocol is based on the incubation of a fixed dose of venom and variable dilutions of 
antivenom, followed by the injection of aliquots of the mixtures in the corresponding assay  
systems [22,33]. Another experimental platform, which is not regularly used, but which is relevant when 
testing antivenoms of variable pharmacokinetic profiles, is based on the injection of venom, followed by 
the administration of antivenom by the intravenous route. This approach does not involve the mixture of 
venom and antivenom before injection and, consequently, reproduces more closely the actual dynamics 
of therapy in the clinical setting.  
Lethality is the single most important effect to be tested when analyzing venom toxicity and its 
neutralization by antivenoms. For the lethality neutralization assay, a “challenge dose”, which usually 
corresponds to 3 to 6 LD50s, depending on the laboratory, is mixed with various dilutions of the 
antivenom, and the mixtures are incubated (generally for 30 min at 37 °C). Control samples include 
venom incubated with saline solution instead of antivenom. The mixtures are then injected in mice,  
either by the intravenous or the intraperitoneal routes, and deaths occurring during a predefined time 
span (24 h or 48 h) are recorded. Neutralization is expressed as the median effective dose (ED50),  
i.e., the antivenom/venom ratio in which 50% of the injected mice survive. Depending on the laboratory, 
ED50 is expressed in various ways, i.e., milligrams of venom neutralized per milligrams of antivenom 
proteins, milligrams of venom neutralized by milliliters of antivenom, milliliters of antivenom required 
to neutralize one milligram of venom or the number of LD50s of venom neutralized per milliliter 
antivenom. The assessment of the ability of antivenoms to neutralize lethality is routinely performed in 
the manufacturers’ quality control laboratories and by national regulatory agencies, as part of regular 
analyses of the antivenoms being manufactured, purchased and distributed. Unfortunately, some 
countries rely mostly on data reported by the manufacturers, rather than on control exerted by regulatory 
agencies. It is necessary to strengthen, through workshops and other activities, the national capacities to 
perform quality control of antivenoms worldwide. 
The neutralization of venom lethality is, and will remain, the gold standard in the preclinical testing of 
antivenom efficacy. However, the study of the biochemical and toxicological complexity of snake 
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venoms has shown clearly that, besides lethality, the venoms of many species induce additional toxic 
activities that play key roles in the pathophysiology of human envenoming. For example, envenomings 
by viperid snakes in many regions around the world are characterized by complex local tissue damage 
(myonecrosis, dermonecrosis, edema, hemorrhage, blistering) and by systemic disturbances 
(hemorrhage, coagulopathy, cardiovascular shock, acute kidney injury). Therefore, a more detailed 
analysis of the preclinical efficacy of antivenoms should encompass, in addition to lethality, the 
neutralization of these other clinically-relevant effects [33–35]. A series of simple in vivo and in vitro 
laboratory assays has been developed for the quantitative assessment of hemorrhagic, myotoxic, 
dermonecrotic, coagulant and defibrinogenating activities, among others [36,38,39]. Thus, although the 
routine quality control of antivenoms involves the neutralization of lethal activity, when a new 
antivenom is being developed or when an existing antivenom is introduced to a new geographical 
setting, a comprehensive preclinical analysis of neutralizing efficacy should be performed against the 
most relevant toxic effects of the most important snake venoms in that particular region. 
The single most important effect in elapid snake venoms is neurotoxicity. Presynaptically-acting 
PLA2s disrupt the integrity of nerve terminal plasma membrane, and post-synaptically-acting 3FTxs 
bind with strong affinity to the nicotinic cholinergic receptor at the motor end-plate, hence causing 
flaccid paralysis, which may result in paralysis of respiratory muscles and death [40]. The preclinical 
efficacy of antivenoms against these venoms can be assessed by the neutralization of lethal effect  
(the ED50 test), since the end result of neurotoxicity is death. Alternatively, neurotoxic activity can be 
assessed by using ex vivo nerve-muscle preparations, such as the phrenic-nerve and biventer-cervicis 
preparations. Venoms of a number of spitting cobras in Africa and Asia induce predominantly a local 
necrotizing effect in humans [40,41]. In these cases, antivenoms should be assessed for their capacity to 
neutralize lethality and dermonecrosis [42]. Sea snake venoms may induce, in addition to a neurotoxic 
effect, a systemic myotoxic action, which might result in rhabdomyolysis. Hence, antivenoms should be 
tested for the neutralization of lethal and myotoxic activities [22]. Venoms of some land Australian 
elapids induce neurotoxicity, myotoxicity and coagulopathy; consequently, preclinical evaluation of 
antivenoms should include the neutralization of these effects [43]. On the other hand, the preclinical 
assessment of antivenoms against viperid venoms should include the analysis of the lethal, hemorrhagic, 
myotoxic, coagulant and defibrinogenating activities of venoms [20]. A brief description of some of 
these methodologies follows. 
(1) Hemorrhagic activity: The most widely-used method is based on the intradermal injection of 
venom solutions, followed, several hours later, by the measurement of the area of the 
hemorrhagic spot in the inner side of the skin [36,44,45]. Venom activity is expressed as the 
minimum hemorrhagic dose (MHD), which corresponds to the dose of venom that induces a 
hemorrhagic halo of 10 mm in diameter. More recently, the analysis of systemic, i.e., pulmonary, 
hemorrhage has been introduced. Mice are injected i.v. with venom, and one hour later, the 
animals are sacrificed and the thoracic cavity exposed for observation of hemorrhagic spots on 
the surface of the lungs. The minimum pulmonary hemorrhagic dose (MPHD) corresponds to the 
lowest amount of venom that induces hemorrhagic spots in the lungs of all mice injected [46]. 
(2) Myotoxic activity: Venom-induced skeletal muscle necrosis can be assessed by histological 
examination of muscle tissue injected with venom. Mice receiving an intramuscular injection of 
venom solution, for example in the gastrocnemius muscle, are sacrificed 24 h later, and the 
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injected muscle is processed for histological analysis. The number of necrotic cells and the total 
number of muscle cells are quantified by microscopic assessment, and the myotoxic effect is 
expressed as the necrotic index, i.e., the ratio of necrotic muscle fibers to total muscle fibers [47]. 
Venom activity can be expressed as the dose inducing a necrotic index of 0.5. Since histological 
analysis is time consuming and not all laboratories have facilities for tissue processing for 
histology, a convenient alternative for the histological analysis is the quantification of the activity 
of the plasmatic enzyme, creatine kinase (CK), which is released from muscle fibers when the 
plasma membrane of muscle cells is disrupted. Mice are injected intramuscularly, as described, 
and a blood sample is collected usually 3 h after injection. After separation of plasma by 
centrifugation, the plasma CK activity is quantified by using commercial kits. The minimum 
myotoxic dose (MMD) is defined as the dose of venom that increases the plasma CK activity  
four times as compared to mice injected with saline solution [48]. 
(3) Dermonecrotic activity: This effect is assessed in either rats or mice by carrying out intradermal 
injections of venom solutions, followed by the measurement of the necrotic area in the inner side 
of the skin 72 h after venom injection [36]. 
(4) Coagulant activity: In vitro coagulant activity of venoms is assessed by the addition of various 
doses of venom to samples of citrated human plasma, obtained from healthy donors, followed by 
the determination of clotting time. Activity is expressed as the minimum coagulant dose (MCD), 
defined as the dose of venom that induces clotting in 60 seconds [36,39]. For assessing the 
thrombin-like activity of venoms, a similar test is performed on fibrinogen solutions instead of 
plasma [36]. 
(5) Defibrinogenating activity: This is assessed in rats or mice by intravenous injection of venom 
solutions. After a defined period of time, a blood sample is collected, placed in a glass tube and 
incubated at room temperature for observation of clot formation. Activity is expressed as the 
minimum defibrinogenating dose (MDD), defined as the dose of venom that induces 
incoagulability, i.e., blood remains unclottable, in all animals injected [36,39]. 
(6) Other tests: Assays for the determination of other toxic activities, such as edema-forming 
activity, ex vivo neurotoxic activity and thrombocytopenic effect, have been described [49–51]. 
The analysis of the neutralization of venom enzyme activities, including neutralization of 
proteinase, phospholipase A2 and hyaluronidase activities, has been also investigated [41,52,53]. 
Similarly to the neutralization of lethality, for the analysis of the neutralization of venom enzyme 
activities, various mixtures of venom:antivenom incubated for 30 min at 37 °C are tested, and 
neutralization of venom activity is expressed as ED50, i.e., the antivenom/venom ratio in which 
the effect of venom is neutralized by 50% [54]. In the case of coagulant and defibrinogenating 
activities, neutralization is expressed as the effective dose (ED), defined as the antivenom/venom 
ratio at which the clotting time of plasma is prolonged three times when compared to plasma 
incubated with venom alone (for coagulant activity) or as the antivenom/venom ratio in which 
blood clots form in all animals injected (for defibrinogenating effect) [39]. 
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3. Omics Toolbox for the Preclinical Assessment of Antivenom Efficacy:  
The Venomics-Antivenomics Platform 
Research on venoms has been continuously enhanced by advances in technology. Progress in  
high-throughput “omics” methodologies and associated instrumentation has catalyzed an expansion of 
the scope of biological research from the biochemical analyses of just a few molecules at a time to the 
systematic and simultaneous study of whole genome sequences, transcriptomes and proteomes. 
Particularly, the last decade has witnessed the introduction of protocols and strategies for unravelling  
the toxin composition of venoms (“venomics”) in great detail, both directly (employing  
proteomics-centered approaches) [20,21,55–57] or indirectly (via cDNA library construction or  
next-generation high-throughput venom gland transcriptomics and bioinformatic analysis) [58,59] in a 
relatively rapid and cost-effective manner (reviewed in [23]). Proteomics-centered venomics requires 
homologous searchable databases to fully exploit its analytical capabilities. In addition, the combination 
of homologous venom proteomics and venom gland transcriptomics can yield complete, or nearly 
complete, locus-specific, assigned venom proteomes [60–62]. Such proteomics characterization of 
snake venoms offers a framework for rationalizing the bioactivities of venoms (Figure 2) and for 
clustering venoms based on within- and between-species shared traits and trends [23]. 
A specific question that has been addressed in recent years using a venomics approach, that is of 
relevance for the treatment of snakebites, concerns the occurrence and onset of geographic and 
ontogenetic shifts in toxin composition within Bothrops [63–66], Crotalus [25,67–69], Sistrurus [70,71], 
Lachesis [72,73] and Gloydius [74] genera. These studies highlight the concept that a species should be 
considered as a group of metapopulations and that within a species range, pedomorphic and ontogenetic 
venom phenotypes often occur in geographically-differentiated areas [23,75]. This knowledge is of 
fundamental importance for the selection of species and specimens for the manufacturing of improved 
therapeutic antivenoms. To aid in antivenom design and to assess the range of the possible clinical 
applications of current commercial or experimental monospecific and polyspecific antivenoms, the 
proteomics-centered protocol, dubbed “antivenomics”, was developed [76,77]. 
Antivenomics complements the in vitro and in vivo venom activity neutralization assays and 
traditional immunological methods, such as ELISA and western blot analyses, for assessing the 
preclinical neutralizing spectrum of antivenoms. Second generation antivenomics [77] is an affinity 
chromatography protocol to investigate the immuno-capturing ability of immobilized IgG, F(ab')2, or 
Fab antibody molecules followed by the proteomic identification of the venom components recovered in 
the retained and the non-bound fractions. The antivenomic analysis provides qualitative and also 
quantitative information on the sets of venom proteins presenting antivenom-recognized epitopes and 
those exhibiting impaired immunoreactivity. While comparing the levels of immune recognition 
gathered from antivenomics with the in vivo neutralization capacity of an antivenom is not straightforward, 
since both experiments involve radically different protocols, in our experience, even a moderate 
immunocapturing capability of ~20%–25% correlates with a good outcome in the in vivo neutralization 
tests. Assuming that the degree of immunorecognition of a toxin by the antivenom’s antibodies 
represents a measure of the capability of this antivenom to neutralize the toxic activity of that toxin,  
the antivenomics analysis may assist in assessing the range of clinical applications of current 
commercial or experimental antivenoms and in the development of improved antivenoms on an 
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immunologically-sound basis. Antivenomics provides thus the grounds for rationalizing the 
paraspecificity of antivenoms and its capability to aid in the formulation of hypotheses as to how venom 
mixtures might be designed or re-designed for the manufacturing of improved therapeutic antivenoms. 
Despite its recent introduction, the usefulness and validity of antivenomics to complement the in vivo 
standard preclinical assays of neutralization of lethality and toxic activities by antivenoms has been 
documented in a number of investigations in recent years [22,23,42,62,73,78–80]. Figure 3 illustrates a 
practical example of this point. 
Figure 2. Venomics complements neutralization assays. Major effects of envenomings by 
the New Guinea small-eyed snake, Micropechis ikaheka, a large and powerfully-built elapid 
endemic to Papua New Guinea and Indonesian West Papua province, include 
life-threatening post-synaptic neuromuscular blockade, resulting in respiratory paralysis, 
PLA2-mediated myotoxicity, hypotension and cardiovascular abnormalities. The venom 
proteome of M. ikaheka is dominated by at least 29 D49-phospholipases A2 (PLA2) and 14 
short and long neurotoxins of the three-finger toxin (3FTx) family [62]. These protein 
classes represent, respectively, 80% and 9.2% of the total venom proteins. Reverse-phase 
HPLC allowed the fractionation of M. ikaheka venom (A) into 3FTx- (B) and PLA2-enriched 
(C) fractions. In vivo neutralization assays showed that PLA2 molecules represent the main 
myotoxic components of M. ikaheka venom. The estimated LD50 for mice of the 
reverse-phase-isolated 3FTx- (0.22 mg/kg) and PLA2- (1.62 mg/kg) enriched fractions, 
indicated that these two toxin classes contribute synergistically to venom lethality  
(0.62 mg/kg), with the 3FTxs playing a dominant role [62]. Reproduced with permission 
from reference [62]. Copyright 2014 Elsevier. 
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Figure 3. Antivenomics complements neutralization assays. The capability of the Costa 
Rican antivenom, EchiTAb-Plus-ICP® [81], to reverse the effects of the venoms of African 
spitting cobras was investigated by neutralization tests [42,77]. EchiTAb-Plus-ICP® 
neutralized the PLA2 and dermonecrotic activities of all of the venoms of African Naja 
snakes sampled. Lethality induced by venoms of the black-necked spitting cobra  
(N. nigricollis), the Mozambique spitting cobra (N. mossambica) and the red spitting cobra 
(N. pallida) was eliminated, but did not prevent the lethal effect of the venoms of the Katian 
spitting cobra (N. katiensis) and the Nubian spitting cobra (N. nubiae). Antivenomics 
analysis showed that the antivenom immunocaptured PLA2 molecules (Peaks 11 and 12 (B) 
and, to a lesser extent, a 3FTx eluted in Peak 16 (B), but had impaired the capability of the 
antivenom to immunodeplete a high abundance type-1 α-neurotoxin (α-NTx) of N. nubiae  
((A) and (C); Peak 1, 12.6% of the total venom proteome) and N. katiensis (4.4%) venoms 
correlated with the pre-clinical inability of EchiTAb-Plus-ICP® antivenom to neutralize the 
lethality of N. nubiae and N. katiensis venoms. Strikingly, although this lethal α-neurotoxin 
was originally purified “from the venom of N. nigricollis collected in Ethiopia in 1961” [82], 
a recent proteomics survey failed to find α-neurotoxin (6,786.7 Da, SwissProt Accession 
Code P01426) in N. nigricollis venoms [42] (D). African spitting cobras have had a long 
history of taxonomic uncertainty. Relevant for rationalizing the “α-toxin paradox”,  
N. nigricollis pallida was elevated to full species status by Branch [83] and Hughes [84]. 
This was later supported by Wüster and Broadley [85], who, in addition, described a new 
species, N. nubiae, in populations previously considered to belong to the Katian spitting 
cobra. α-Neurotoxin is expressed in venoms of N. pallida and N. nubiae (reverse-phase 
HPLC Peak 1, in (A) and (E), respectively), but is virtually absent from the other African 
spitting Naja venoms investigated. Thus, the failure of the EchiTAb-Plus-ICP® antivenom to 
neutralize the lethal activity of the Nubian and Katian spitting cobra venoms may be due to 
the absence of α-neurotoxin epitopes in the N. nigricollis venom (D) employed in the 
immunization mixture to generate this antivenom. The “α-neurotoxin paradox”, resolved by 
combining neutralization assays and antivenomics, underpins the importance of getting the 
taxonomy right for the development of a strategy for the improvement of antivenoms. 
 
Toxins 2014, 6 3398 
 
 
Figure 3. Cont. 
 
4. Concluding Remarks 
The shortage of antivenoms in various parts of the planet can be in part counteracted through the 
improved deployment of currently existing antivenoms, but also through the design and production of 
next-generation polyspecific antivenoms of a wide neutralizing spectrum. Venomics-guided uncovering 
of evolutionary convergent compositional and immunological trends between homologous and 
heterologous snake venoms may help in the design of such broad specificity antidotes. For this purpose, 
the choice of immunization mixture cannot be based on phylogenetic distance, but on a deep 
understanding of the intraspecific venom variation of the medically-important snakes across the 
geographical range where the antivenom will be deployed. A deep understanding of the venom toxin 
profile and the identification of divergent and convergent trends along the evolutionary history of 
venoms have significant implications for selecting the most appropriate species and specimens for 
manufacturing antivenoms exhibiting an improved therapeutic scope. Antivenomics represents a 
knowledge-based approach to help in designing improved venom-based immunogen mixtures and to 
predict paraspecific neutralization by antivenom preparations to the level of species-specific toxins. 
Accumulating evidence shows the potential of the combination of antivenomics and neutralization 
assays for analyzing at the molecular level the preclinical efficacy of antivenoms against homologous 
and heterologous venoms. 
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